<DOC>
	<DOCNO>NCT00723489</DOCNO>
	<brief_summary>The main objective Atopic Dermatitis Vaccinia Immunization Network ( ADVN ) reduce risk fatal reaction , eczema vaccinatum ( EV ) , smallpox vaccination atopic dermatitis ( AD ) . Since vaccination live vaccinia virus ( VV ) individual AD increase risk EV , yellow fever vaccine choose . The purpose study determine immune response yellow fever vaccine adult AD .</brief_summary>
	<brief_title>Immune Response Yellow Fever Vaccination Adults With Atopic Dermatitis</brief_title>
	<detailed_description>AD chronic inflammatory skin disorder characterize recurrent viral skin infection . The purpose study understand immune response yellow fever vaccine adult AD . This study provide substantial information normal defective cutaneous immunity participant AD response live virus vaccine , critical understanding EV reaction . An individual 's participation study last 13 week . Participants randomize one two arm . The first experimental arm consist 20 adult AD 20 healthy adult . They receive one dose YFV-17D subcutaneous administration right deltoid receive one dose YFV-17D placebo transcutaneous administration leave deltoid . The second arm consist 20 adult AD 20 healthy adult . They receive one dose YFV-17D placebo subcutaneous administration right deltoid receive one dose YFV-17D vaccine transcutaneously leave deltoid . This study consist 6 follow-up visit 35 day period study entry .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Yellow Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis Atopic Dermatitis Nonatopic control Born currently reside United States Weight least 110 lbs Screening Visit Not previously vaccinate YFV , tickborne encephalitis ( TBEV ) , Japanese encephalitis virus ( JEV ) , dengue fever Agree use adequate contraception 30 day prior participation study complete . More information criterion find protocol . AD subject exfoliative erythroderma lack minimum 10 cm diameter area normal appear skin deltoid thigh vaccination site Have body mass index ( BMI ) 30 great Screening Visit Known history infection YFV , dengue fever , TBEV , JEV , West Nile Virus ( WNV ) A family history severe reaction yellow fever vaccine Traveled Africa South America ( include participant plan travel area prior completion study ) History egg allergy positive egg allergy skin prick test administer Screening visit History acute hypersensitivity reaction component yellow fever vaccine ( include gelatin ) Have latex allergy Have lidocaine allergy Are allergic hypersensitive TegadermTM Received systemic immunosuppressant within 30 day prior receive vaccination Received systemic corticosteroid , anti inflammatory biologics ( e.g. , alefacept , etanercept , etc . ) , calcineurin inhibitor within 30 day prior receive vaccination Received systemic antibiotic antiviral within 7 day receive vaccination Received great 440 mcg inhale steroid per day within 6 month prior receive vaccination Received Xolair ( Omalizumab ) within 1 year prior receive vaccination Received immunotherapy within 30 day prior receive vaccination Received vaccine within 30 day prior randomization expect receipt 30 day randomization Received topical antibiotic , antiviral , immune enhancer ( e.g. , imiquimod ) , calcineurin inhibitor within 7 day prior receive vaccination Received topical corticosteroid within 7 day prior receive vaccination Received phototherapy ( e.g. , ultraviolet light B [ UVB ] , psoralen plus ultraviolet light A [ PUVA ] ) within 30 day prior receive vaccination Acute febrile illness active fungal , bacterial , viral infection ( subject may reconsider enrollment condition resolve ) Skin disease AD might compromise stratum corneum barrier ( e.g. , clinically evident ichthyosis , bullous disease , psoriasis ) Current past history malignancy autoimmune immunodeficiency disease . More information criterion find protocol . Pregnant breastfeeding Have antinuclear antibody ( ANA ) titer equal great 1/160 Screening Visit Have serum immunoglobulin ( Ig ) G , IgM , IgA , C3 , C4 level normal range Screening Visit Have manual lymphocyte count less 1000 lymphocyte per microliter</criteria>
	<gender>All</gender>
	<minimum_age>27 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Yellow Fever Vaccine</keyword>
	<keyword>Scarification Method</keyword>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>IgG antibody</keyword>
</DOC>